4D Molecular Therapeutics, Inc. FDMT
12.50 USD +1.25 (+11.11%)
Nov 6, 2026, 1:39 PM EST
11.28 Day range 12.57
6.96 52-week range 16.93
- YTD
- +66.67%
- 1 year
- +14.47%
News
globenewswire.com 4DMT to Participate in Upcoming Investor Conferences EMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted…
zacks.com 4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? 4D Molecular Therapeutics (FDMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $36 price target.
benzinga.com General Motors, Genuine Parts, Steel Dynamics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures were mixed as GM shares fell 7.3% despite an earnings beat; FreightCar America, 4D Molecular and others also declined premarket.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their…
benzinga.com Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25 Chardan Capital analyst Gautam Chukka maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $26 to $25.
benzinga.com B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33 B of A Securities analyst Tazeen Ahmad maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $29 to $33.
benzinga.com Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures rose, but Scholastic plunged 9.9% after missing Q1 loss and sales estimates; several other stocks also fell premarket.
benzinga.com This Coinbase Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday Analysts upgraded Coinbase, 4D Molecular Therapeutics, Affirm, Chime Financial and Bullish, raising ratings and price targets.- benzinga.com Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target Cantor Fitzgerald analyst Josh Schimmer upgrades 4D Molecular Therapeutics (NASDAQ:FDMT) from Neutral to Overweight and announces $20 price target.
benzinga.com B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37 B. Riley Securities analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and announces Price Target of $37.
benzinga.com 4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win 4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to an 87% cut in treatment burden.
benzinga.com HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $36 price target.- benzinga.com Reported Saturday, 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In Recently Diagnosed Wet Age-Related Macular Degeneration Subgroup After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well…
- benzinga.com 4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evaluating 4D-150 In Patients With Wet Age-Related Macular Degeneration 4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting…
benzinga.com 4D Molecular Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $3.047M Miss $5.167M Estimate 4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.99) by 2.02 percent. This is a 17.44 percent decrease over…
benzinga.com HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $36 price target.- benzinga.com RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35 RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price target from $32 to $35.
- benzinga.com UPDATE: 4D Molecular Therapeutics Q4 EPS $0.43 Beats $(0.53) Estimate, Sales $85.090M Beat $32.245M Estimate 4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $(0.53) by 181.13 percent. This is a 147.78 percent increase over…
- benzinga.com 4D Molecular Therapeutics Completes Patient Enrollment In 4FRONT-1 Trial Evaluating 4D-150 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment…
benzinga.com Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings) 
benzinga.com BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session - benzinga.com Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $26 Price Target Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $26 price target.
- benzinga.com 4D Molecular Therapeutics Says Interim Data From 4D-710 Phase 1 AEROW Trial For Cystic Fibrosis Lung Disease Shows Meaningful Lung Function Activity Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic…
- benzinga.com RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $32 RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price target from $26 to $32.
- benzinga.com Barclays Maintains Overweight on 4D Molecular Therapeutics, Lowers Price Target to $33 Barclays analyst Gena Wang maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight and lowers the price target from $38 to $33.
- benzinga.com Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $26 Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $25 to $26.
- benzinga.com 4D Molecular Therapeutics Q3 EPS $(1.01) Misses $(0.98) Estimate, Sales $90.000K Miss $287.857K Estimate 4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.98) by 3.27 percent. This is a 27.85 percent decrease over…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com 4D Molecular Therapeutics Prices $100M Offering Including 8.4M Common Shares At $10.51 Each And 1.1M Pre-Funded Warrants At $10.5099 Each 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment…- benzinga.com 4DMT's 4D-150 Demonstrates Durable, Multi-Year Benefit Supporting Its Potential As A Backbone Therapy For Wet AMD And Retinal Diseases 4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all…
- benzinga.com Reported Earlier, 4DMT And Otsuka Pharmaceutical Sign $85M Upfront License Deal With Up To $336M In Milestones To Develop And Commercialize 4D-150 Across Asia-Pacific 4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global…
- benzinga.com Beyond The Numbers: 4 Analysts Discuss 4D Molecular Therapeutics Stock
- benzinga.com RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $26 Price Target RBC Capital analyst Lisa Walter reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $26 price target.
- benzinga.com 10 Health Care Stocks Whale Activity In Today's Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Jim Cramer: AppLovin Calls For Prudence, This Health Care Stock Is 'Pure Spec' Jim Cramer doesn't recommend buying more AppLovin stock. "Let's take a little off the table just to be prudent," he said.- benzinga.com What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics
- benzinga.com Roth Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $38 Roth Capital analyst Salveen Richter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $44 to $38.
- benzinga.com Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $25 Price Target Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $25 price target.
benzinga.com 4D Molecular Therapeutics Q2 EPS $(0.98) Misses $(0.85) Estimate, Sales $15.000K Miss $374.143K Estimate 4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.85) by 14.75 percent. This is a 55.56 percent decrease over…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Assessing 4D Molecular Therapeutics: Insights From 5 Financial Analysts
benzinga.com 4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study 4D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Market-Moving News for August 1st FIG: 28% | Figma shares are trading higher on momentum following Thursday's IPO. COIN: -11% | Coinbase shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS and
benzinga.com Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 4DMT Presents Results Of 4D-150 SPECTRA Clinical Trial In DME And Regulatory Update 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in…
- benzinga.com What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics